Mizagliflozin is an inhibitor of the sodium-glucose cotransporter SGLT1 that was developed as a potential treatment for chronic constipation. According to its encyclopedia article it progressed as far as phase II trials in humans but was not approved for medical use, although it has since been investigated for other applications. It is recorded here as an investigational compound, an example of a drug candidate whose original target indication did not lead to approval. This entry is a record of what the source lead states and is not medical advice.
Facts
Drug ClassSelective sodium glucose co-transporter 1 (SGLT1) inhibitor 2 Mechanism of ActionPotently inhibits human SGLT1 in a highly selective manner 2 Classification
Approval Status Route of Administration Connections
Sources
1. Mizagliflozin (Wikipedia)
Lead paragraphQuote, Lead paragraph
was not approved for medical use
2. Mizagliflozin, a novel selective SGLT1 inhibitor, exhibits potential in the amelioration of chronic constipation (Eur J Pharmacol 2017)
Abstract, opening sentences
Herein, we report the potential of mizagliflozin, a novel selective sodium glucose co-transporter 1 (SGLT1) inhibitor,
Abstract, results
Mizagliflozin potently inhibited human SGLT1 in a highly selective manner.
Abstract, phase I study methods
The safety profile of an initial single dose (2-160mg, orally) and multiple doses (2-20mg, orally,
View the SourceNCBI E-utilities abstract record for PubMed article 28410751
Abstract, resultsQuote, Abstract, results
The results of the phase I study showed mizagliflozin increased stool frequency and loosened stool consistency
Reader Challenges (0)
No disputes yet. Spotted an error or a better source? Open the first one.
Sign in to dispute this or suggest a correction.